Anavex Life Sciences

AVXL

Market cap $774M

Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine”

Anavex Life Sciences Corp. reported positive phase 2 results for ANAVEX 3-71 in schizophrenia, showing improved biomarkers and strong safety. AVXL's ANAVEX 3-71 targets all three schizophrenia domains—positive, negative, and cognitive symptoms—offering a holistic, competitive oral therapy. The company maintains a solid cash position, supporting operations for at least three years, with flexible financing options in place if needed.

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults

ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, today announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX®3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication (ANAVEX3-71-SZ-001, NCT06245213). The study successfully achieved its primary endpoint, demonstrating that ANAVEX®3-71 was safe and well-tolerated.

Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients” Significant improvement in self-assessed Quality of Life (QoL-AD) scores indicating a reversal of negative trajectory for Alzheimer's disease clinical trial participants was observed Using a novel Precision Medicine approach, up to ~70% of Alzheimer's disease participants benefited with unprecedented effect size Oral blarcamesine tablet, by enhancing the brain's autophagy internal clearing mechanism could alleviate significant medical and economic burden Publication available on medRxiv, in submission to a peer-reviewed medical journal NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the publication “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients” to be available online as a preprint at medRxiv, and in submission to a peer-reviewed medical journal.

New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's disease

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today announced that Christopher U.

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported a peer-reviewed publication in the journal iScience, ascertaining the precise autophagy mechanism of sigmar-1 receptor (S1R/SIGMAR1) through blarcamesine activation, titled “Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP.”1

Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported a peer-reviewed publication in the journal Neuroscience Letters, titled “Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer's disease model.”1 This study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury suggesting that blarcamesine is an attractive candidate for Alzheimer's disease pharmacological prevention.

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Christopher U. Missling - President, CEO, Secretary & Director Clint Tomlinson - VP of Corporate Sandra Boenisch - Principal Financial Officer & Treasurer Conference Call Participants Jesse Silveira - Unidentified Company Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Tom Bishop - BI Research Clint Tomlinson Good morning, and welcome to the Anavex Life Sciences Fiscal 2025 Third Quarter Conference Call.